VistaGen Therapeutics (VTGN) News Today $2.91 -0.34 (-10.46%) Closing price 04:00 PM EasternExtended Trading$2.96 +0.05 (+1.75%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTGN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Significant Growth in Short InterestSeptember 16 at 8:37 AM | marketbeat.comVistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy SummitSeptember 9, 2025 | businesswire.comVistaGen Therapeutics, Inc. $VTGN Shares Bought by ADAR1 Capital Management LLCSeptember 4, 2025 | marketbeat.comVistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety TrialSeptember 2, 2025 | sg.finance.yahoo.comWhile institutions invested in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) benefited from last week's 11% gain, retail investors stood to gain the mostAugust 17, 2025 | finance.yahoo.comVistaGen Therapeutics (NASDAQ:VTGN) Rating Increased to Hold at Wall Street ZenAugust 17, 2025 | marketbeat.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call TranscriptAugust 12, 2025 | msn.comVistaGen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Meets EstimatesAugust 10, 2025 | marketbeat.comVistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ...August 8, 2025 | finance.yahoo.comVistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comQ1 2026 Vistagen Therapeutics Inc Earnings Call TranscriptAugust 8, 2025 | gurufocus.comVistagen (VTGN) Q1 R&D Expense Jumps 54%August 7, 2025 | fool.comVistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate UpdateAugust 7, 2025 | businesswire.comVistaGen Therapeutics Q1 2026 Earnings PreviewAugust 6, 2025 | msn.comVistaGen Therapeutics (VTGN) to Release Earnings on ThursdayAugust 2, 2025 | marketbeat.comVistagen to Present at the BTIG Virtual Biotechnology ConferenceJuly 24, 2025 | businesswire.comVistaGen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50-Day Moving Average - Time to Sell?July 16, 2025 | marketbeat.comVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipJuly 15, 2025 | businesswire.comVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipJuly 15, 2025 | businesswire.comStifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 DelayJuly 3, 2025 | msn.comVTGN Vistagen Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comVistagen Appoints Elissa Cote as Chief Corporate Development OfficerJune 25, 2025 | businesswire.comVistagen Therapeutics, Inc. (VTGN) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comWilliam Blair Issues Negative Forecast for VTGN EarningsJune 23, 2025 | marketbeat.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call TranscriptJune 22, 2025 | insidermonkey.comWilliam Blair Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)June 20, 2025 | theglobeandmail.comVistagen Therapeutics’ Earnings Call Highlights Progress and ChallengesJune 19, 2025 | tipranks.comWhat is William Blair's Forecast for VTGN Q1 Earnings?June 19, 2025 | marketbeat.comVistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William BlairJune 18, 2025 | marketbeat.comVistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...June 18, 2025 | finance.yahoo.comVistagen Therapeutics Reports Progress in Clinical TrialsJune 17, 2025 | tipranks.comVistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call TranscriptJune 17, 2025 | seekingalpha.comVistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPSJune 17, 2025 | marketbeat.comVistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate UpdateJune 17, 2025 | businesswire.comInsights into VistaGen Therapeutics's Upcoming EarningsJune 16, 2025 | benzinga.comVistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look ForJune 16, 2025 | gurufocus.comVistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025June 12, 2025 | businesswire.comVistagen Therapeutics (VTGN) to Release Earnings on TuesdayJune 3, 2025 | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Shares Pass Above 50 Day Moving Average - Should You Sell?May 28, 2025 | marketbeat.comVistagen to Present at the 2025 American Society of Clinical Psychopharmacology ConferenceMay 23, 2025 | businesswire.comRenaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)May 8, 2025 | marketbeat.comAlmitas Capital LLC Purchases New Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)May 4, 2025 | marketbeat.comVistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Bought by Nantahala Capital Management LLCApril 30, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)April 26, 2025 | marketbeat.comVistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 ConferenceApril 17, 2025 | businesswire.comVistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average - Should You Sell?March 21, 2025 | marketbeat.comVistaGen at Stifel 2025: Pioneering Acute SAD TreatmentMarch 20, 2025 | investing.comVistagen to Present at the 2025 Anxiety and Depression Association ConferenceMarch 19, 2025 | businesswire.comVistagen Therapeutics (NASDAQ:VTGN) Stock Crosses Below 50 Day Moving Average - Should You Sell?March 11, 2025 | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50 Day Moving Average - Here's WhyFebruary 22, 2025 | marketbeat.com Get VistaGen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VTGN Media Mentions By Week VTGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTGN News Sentiment▼0.710.92▲Average Medical News Sentiment VTGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTGN Articles This Week▼31▲VTGN Articles Average Week Get the Latest News and Ratings for VTGN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for VistaGen Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SLDB News ATXS News NBTX News FULC News CGEM News KMDA News INBX News AURA News ADCT News PRTC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTGN) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VistaGen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VistaGen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTGN Stock Alerts